An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Open Access
- 19 March 2015
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 125 (12), 1857-1865
- https://doi.org/10.1182/blood-2014-10-607341
Abstract
Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future clinical trials with the principal objective of establishing suitable treatment algorithms. An international panel comprising laboratory and clinical experts in MDS/MPN was established involving 3 independent academic MDS/MPN workshops (March 2013, December 2013, and June 2014). These recommendations are the result of this collaborative project sponsored by the MDS Foundation.Keywords
This publication has 65 references indexed in Scilit:
- Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groupsHaematologica, 2013
- OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CMLNew England Journal of Medicine, 2013
- Recurrent SETBP1 mutations in atypical chronic myeloid leukemiaNature Genetics, 2012
- Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3APublished by American Society of Hematology ,2011
- Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignanciesBlood, 2011
- Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutationsLeukemia Research, 2010
- Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemiaBlood, 2010
- Mutations in CBL occur frequently in juvenile myelomonocytic leukemiaBlood, 2009
- Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasmsBlood, 2009
- Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutationBlood, 2006